skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Dabrafenib (Code C82386)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Dabrafenib

Definition: An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.

Display Name: Dabrafenib

Label: Dabrafenib

NCI Thesaurus Code: C82386 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3467876  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-
BRAF Inhibitor GSK2118436

External Source Codes: 
CAS Registry Number 1195765-45-7 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 641977
PDQ Open Trial Search ID 641977 (check for NCI PDQ open clinical trial info)
UMLS CUI C3467876

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation
Chemical_Formula C23H20F3N5O2S2
code C82386
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name BRAF_Inhibitor_GSK2118436
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom